Literature DB >> 17121936

Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4.

Peter Thomson1, Matthew A Naylor, Steven A Everett, Michael R L Stratford, Gemma Lewis, Sally Hill, Kantilal B Patel, Peter Wardman, Peter D Davis.   

Abstract

Nitrothienylprop-2-yl ether formation on the 3'-phenolic position of combretastatin A-4 (1) abolishes the cytotoxicity and tubulin polymerization-inhibitory effects of the drug. 5-Nitrothiophene derivatives of 1 were synthesized following model kinetic studies with analogous coumarin derivatives, and of these, compound 13 represents a promising new lead in bioreductively targeted cytotoxic anticancer therapies. In this compound, optimized gem-dimethyl alpha-carbon substitution enhances both the aerobic metabolic stability and the efficiency of hypoxia-mediated drug release. Only the gem-substituted derivative 13 released 1 under anoxia in either in vitro whole-cell experiments or supersomal suspensions. The rate of release of 1 from the radical anions of these prodrugs is enhanced by greater methyl substitution on the alpha-carbon. Cellular and supersomal studies showed that this alpha-substitution pattern controls the useful range of oxygen concentrations over which 1 can be effectively released by the prodrug.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17121936     DOI: 10.1158/1535-7163.MCT-06-0429

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  10 in total

1.  Synthesis and Biological Evaluation of Benzocyclooctene-based and Indene-based Anticancer Agents that Function as Inhibitors of Tubulin Polymerization.

Authors:  Christine A Herdman; Tracy E Strecker; Rajendra P Tanpure; Zhi Chen; Alex Winters; Jeni Gerberich; Li Liu; Ernest Hamel; Ralph P Mason; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney
Journal:  Medchemcomm       Date:  2016-09-22       Impact factor: 3.597

2.  Bioreductively activatable prodrug conjugates of phenstatin designed to target tumor hypoxia.

Authors:  Blake A Winn; Zhe Shi; Graham J Carlson; Yifan Wang; Benson L Nguyen; Evan M Kelly; R David Ross; Ernest Hamel; David J Chaplin; Mary L Trawick; Kevin G Pinney
Journal:  Bioorg Med Chem Lett       Date:  2016-12-01       Impact factor: 2.823

Review 3.  Targeting hypoxia in cancer therapy.

Authors:  William R Wilson; Michael P Hay
Journal:  Nat Rev Cancer       Date:  2011-06       Impact factor: 60.716

4.  Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.

Authors:  Blake A Winn; Laxman Devkota; Bunnarack Kuch; Matthew T MacDonough; Tracy E Strecker; Yifan Wang; Zhe Shi; Jeni L Gerberich; Deboprosad Mondal; Alejandro J Ramirez; Ernest Hamel; David J Chaplin; Peter Davis; Ralph P Mason; Mary Lynn Trawick; Kevin G Pinney
Journal:  J Nat Prod       Date:  2020-03-20       Impact factor: 4.050

5.  Development of water soluble derivatives of cis-3, 4', 5-trimethoxy-3'-aminostilbene for optimization and use in cancer therapy.

Authors:  David E Durrant; Joanna Richards; Ashutosh Tripathi; Glen E Kellogg; Paolo Marchetti; Marco Eleopra; Giuseppina Grisolia; Daniele Simoni; Ray M Lee
Journal:  Invest New Drugs       Date:  2008-05-31       Impact factor: 3.850

6.  Reversion of apoptotic resistance of TP53-mutated Burkitt lymphoma B-cells to spindle poisons by exogenous activation of JNK and p38 MAP kinases.

Authors:  M Farhat; A Poissonnier; A Hamze; C Ouk-Martin; J-D Brion; M Alami; J Feuillard; C Jayat-Vignoles
Journal:  Cell Death Dis       Date:  2014-05-01       Impact factor: 8.469

Review 7.  Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy.

Authors:  William A Denny
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-02

8.  Demonstrating Tumor Vascular Disrupting Activity of the Small-Molecule Dihydronaphthalene Tubulin-Binding Agent OXi6196 as a Potential Therapeutic for Cancer Treatment.

Authors:  Li Liu; Regan Schuetze; Jeni L Gerberich; Ramona Lopez; Samuel O Odutola; Rajendra P Tanpure; Amanda K Charlton-Sevcik; Justin K Tidmore; Emily A-S Taylor; Payal Kapur; Hans Hammers; Mary Lynn Trawick; Kevin G Pinney; Ralph P Mason
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

Review 9.  Tubulin-interactive stilbene derivatives as anticancer agents.

Authors:  Renata Mikstacka; Tomasz Stefański; Jakub Różański
Journal:  Cell Mol Biol Lett       Date:  2013-07-01       Impact factor: 5.787

10.  Facile synthesis of heterocycles via 2-picolinium bromide and antimicrobial activities of the products.

Authors:  Elham S Darwish
Journal:  Molecules       Date:  2008-05-01       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.